On Sept. 30, 2025, Zoetis announced that Dectomax^®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls.

Zoetis is committed to supporting livestock producers with scientific solutions for this economically devastating pest. New World screwworm poses a continuing threat to livestock health, and the financial impacts of the disease to the U.S. agricultural economy are estimated in the billions of dollars.

Early detection of New World screwworm and rapid response are critical to protecting the health of animals and the livestock industry. Producers are encouraged to immediately report any suspicious wounds, maggots, or infestations to their local accredited veterinarian, state animal health official, or the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service.

In the first half of 2026, producers and veterinarians will begin to see the 250-milliliter and 500-milliliter bottles of Dectomax^® Injectable with a new label for Dectomax^®-CA1 (doramectin injection). Dectomax-CA1 is the same effective doramectin formulation as Dectomax Injectable.

Dectomax and Dectomax-CA1 Injectable for use in cattle have a 35-day pre-slaughter withdrawal period. Do not use in female dairy cattle 20 months of age or older. Do not use in calves to be processed for veal. Dectomax Injectable for use in swine has a 24-day pre-slaughter withdrawal period. Use of Dectomax or Dectomax-CA1 in dogs may result in fatalities.